211 related articles for article (PubMed ID: 32817374)
1. Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability.
Kharat SS; Ding X; Swaminathan D; Suresh A; Singh M; Sengodan SK; Burkett S; Marks H; Pamala C; He Y; Fox SD; Buehler EC; Muegge K; Martin SE; Sharan SK
Sci Signal; 2020 Aug; 13(645):. PubMed ID: 32817374
[TBL] [Abstract][Full Text] [Related]
2. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
Rondinelli B; Gogola E; Yücel H; Duarte AA; van de Ven M; van der Sluijs R; Konstantinopoulos PA; Jonkers J; Ceccaldi R; Rottenberg S; D'Andrea AD
Nat Cell Biol; 2017 Nov; 19(11):1371-1378. PubMed ID: 29035360
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
[TBL] [Abstract][Full Text] [Related]
5. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
Meghani K; Fuchs W; Detappe A; Drané P; Gogola E; Rottenberg S; Jonkers J; Matulonis U; Swisher EM; Konstantinopoulos PA; Chowdhury D
Cell Rep; 2018 Apr; 23(1):100-111. PubMed ID: 29617652
[TBL] [Abstract][Full Text] [Related]
7. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
[TBL] [Abstract][Full Text] [Related]
8. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
9. PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.
Kim JJ; Lee SY; Choi JH; Woo HG; Xhemalce B; Miller KM
Mol Cell; 2020 Oct; 80(2):327-344.e8. PubMed ID: 32966758
[TBL] [Abstract][Full Text] [Related]
10. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
11. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
12. Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
Clements KE; Thakar T; Nicolae CM; Liang X; Wang HG; Moldovan GL
Nucleic Acids Res; 2018 Sep; 46(17):8898-8907. PubMed ID: 30032296
[TBL] [Abstract][Full Text] [Related]
13. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
16. N
Fukumoto T; Zhu H; Nacarelli T; Karakashev S; Fatkhutdinov N; Wu S; Liu P; Kossenkov AV; Showe LC; Jean S; Zhang L; Zhang R
Cancer Res; 2019 Jun; 79(11):2812-2820. PubMed ID: 30967398
[TBL] [Abstract][Full Text] [Related]
17. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
18. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
[TBL] [Abstract][Full Text] [Related]
19. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
[TBL] [Abstract][Full Text] [Related]
20. Targeting the nucleotide salvage factor DNPH1 sensitizes
Fugger K; Bajrami I; Silva Dos Santos M; Young SJ; Kunzelmann S; Kelly G; Hewitt G; Patel H; Goldstone R; Carell T; Boulton SJ; MacRae J; Taylor IA; West SC
Science; 2021 Apr; 372(6538):156-165. PubMed ID: 33833118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
